Will US FDA Remove Higher Strength Opioids From The Market?
Executive Summary
Advisory committee members are divided on whether agency should restrict access to higher dose opioids, but most want option kept on the table.
You may also be interested in...
How To Label Rx Drugs for Abuse And Dependence: US FDA Gives Directions For Consistency
Labeling should include signs and symptoms of withdrawal as well as abuse-deterrent properties, draft guidance states.
New Opioids May Need Comparative Effectiveness Data For Approval
Draft guidance says US FDA will consider product's benefit-risk balance relative to approved analgesics; it is particularly interested in comparative efficacy and safety data.
How To Deal With High Dose Opioids: Better Storage, Disposal And Advertising
Beyond considering removal from the market, US FDA advisory panel suggests actions agency could take to improve the safety of higher dosage strength opioids.